{"url_path":"/sec/kynb/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/921299/0001193125-26-271449-index.html","accession_number":"0001193125-26-271449","cik":"0000921299","ticker":"KYNB","issuer_name":"KYNTRA BIO, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/921299/0001193125-26-271449-index.html","primary_entity_key":"0000921299","primary_entity_name":"KYNTRA BIO, INC."},"word_count":313,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nAt the 2026 annual meeting of stockholders of Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) held on June 12, 2026, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2026 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 27, 2026. The results of the matters voted upon at the meeting were:\n\n \n\n(1)\n\n \n\nThe Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company’s 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes.\n\nThe term of office of Class I directors Thane Wettig, James A. Schoeneck, and Maykin Ho, Ph.D. continues until the Company’s 2027 annual meeting of stockholders. The term of office of Class II director Jeffrey L. Edwards continues until the Company’s 2028 annual meeting of stockholders.\n\n(2)\n\n \n\nThe stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.\n\n(3)\n\n \n\nThe stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the Kyntra Bio board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2026: 2,712,825 shares of Common Stock voted for, 14,392 against, and 7,461 abstaining.\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nKYNTRA BIO, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ John Alden\n\n \n\n \n\n \n\nJohn Alden\nGeneral Counsel"}